益佰品牌怎么样申请店铺

我要投票

益佰在医疗保健行业中的票数：514 更新时间：2025-08-15

益佰是哪个国家的品牌？「益佰」是贵州益佰制药股份有限公司旗下著名品牌。该品牌发源于贵州省贵阳市，由创始人窦董在1995年期间创立，经过多年的不懈努力和高速发展，现已成为行业的标杆品牌。

外推网助力益佰品牌出海！将品牌入驻外推网，定制益佰品牌推广信息，可以显著提高益佰产品曝光，简直是跨境电商爆单神器！目前仅需1000元/年哦~

贵州益佰制药股份有限公司，知名医药品牌，主要有克咳家族系列/艾迪注射液/银杏达莫注射液/注射用洛铂/前列癃闭通颗粒等产品，集新型药品的研究、开发、生产和销售为一体的高新技术企业

贵州益佰制药股份有限公司是一家集新型药品的研究、开发、生产和销售为一体的企业。公司创建于1995年6月12日，2000年11月完成股份制改造，并于2004年3月在上海证券交易所成功上市(证券代码600594)。

公司占地面积134398平方米，建有符合国家药品生产质量管理规范(简称GMP)的生产厂房43200平方米。目前拥有省内生产基地3个，省外生产基地4个。现有小针剂、冻干粉针、大输液等49个品规产品，9条注射剂生产线。配备有国际先进水平的生产设备。

公司目前的主要产品有克咳家族系列、艾迪注射液、银杏达莫注射液、注射用洛铂、复方斑蝥胶囊、理气活血滴丸、前列癃闭通颗粒等众多优势品种。在这些已形成企业优势系列产品中，复方中药针剂艾迪注射液和复方斑蝥胶囊为双相抗肿瘤新药，其中艾迪注射液的研究已达到基因水平;第四代银杏制剂----银杏达莫注射液，是心、脑血管及外周循环障碍的有效治疗药物，它的面世为广大的心脑血管病患者带来了福音;注射用洛铂是国家一类新药，第三代铂类抗肿瘤药物，相对其他铂类，其毒性较低、耐药性较小。理气活血滴丸则是独家原研苗药，是治疗心血管疾病的一线用药，具有极大的市场潜力。

一直以来，公司十分重视知识产权的保护工作，2004年就成立了专门的知识产权部门，并采取了申请专利保护，注重发展核心技术，提升企业自主创新能力。其中，公司申请了发明专利199件，授权115件;申请外观专利82件，授权76件。完成临床前研究及注册申报94项，实施临床研究7项，获得生产批文共计27件。

Guizhou Yibai Pharmaceutical Co., Ltd. is a well-known pharmaceutical brand, mainly including Keke family series / Aidi injection / gingko Damo injection / lobaplatin for injection / qianliehuangrentong granules and other products. Guizhou Yibai Pharmaceutical Co., Ltd. is a high-tech enterprise integrating research, development, production and sales of new drugs Sales as one of the enterprises. The company was founded on June 12, 1995, completed the share-holding transformation in November 2000, and successfully listed on the Shanghai Stock Exchange in March 2004 (Stock Code: 600594). The company covers an area of 134398 square meters, and has built 43200 square meters of production plant in line with the GMP. At present, it has 3 production bases in the province and 4 production bases outside the province. There are 49 products and 9 injection production lines including small injection, freeze-dried powder injection and large infusion. Equipped with internationally advanced production equipment. At present, the company's main products include Keke family series, Aidi injection, gingko Damo injection, lobaplatin for injection, compound cantharis capsule, Liqihuoxue dropping pill, qianliehuangaotong granules and many other superior varieties. Among these products, Aidi injection and cantharis capsule are two-phase anti-tumor drugs, among which the research of Aidi injection has reached the level of gene; The fourth generation of Ginkgo biloba preparation, Ginkgo biloba Damo injection, is an effective drug for the treatment of heart, cerebrovascular and peripheral circulation disorders. Its appearance has brought good news to the vast number of patients with cardiovascular and cerebrovascular diseases. Lotplatin for injection is a new drug of the state. The third generation of platinum antitumor drugs, compared with other platinum, has lower toxicity and less drug resistance. Liqihuoxue dropping pill is the exclusive original vaccine drug, which is the first-line drug for the treatment of cardiovascular diseases and has great market potential. The company has always attached great importance to the protection of intellectual property. In 2004, it established a special intellectual property department, and applied for patent protection, focused on the development of core technology, and improved the ability of independent innovation of enterprises. Among them, the company has applied for 199 invention patents and authorized 115; applied for 82 appearance patents and authorized 76. 94 pre clinical studies and registration applications were completed, 7 clinical studies were carried out, and 27 production approvals were obtained.

本文链接： https://brand.waitui.com/27dbf8bc8.html 联系电话：请联系客服添加联系邮箱：请联系客服添加